National LTC Pharmacy Group Praises Trump White House Report Targeting PBM “Lack of Transparency”
Report Says Policies to Disrupt PBM Oligopoly “Can Reduce the Price of Drugs Paid by Consumers”…Read More.
Desperate Fig Leaf: PBM Effort to Use Non-Interference Clause to Systematize Price-Gouging
From the standpoint of the widening national debate on drug pricing issues, 2017 was a watershed year…Read more.
Senior Care Pharmacy Coalition Comments on Healthcare Choice and Competition
January 25, 2018 Via Electronic Submission: CompetitionRFI@hhs.gov John R. Graham Acting Assistant Secretary for Planning and Evaluation Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201 Re: Response to RFI: Promoting Healthcare Choice and Competition Dear Mr. Graham: The Senior Care Pharmacy Coalition (SCPC) commends the office of the Assistant Secretary read more…
Senior Care Pharmacy Coalition (SCPC) Slams PBM Industry Attempt to Hide Behind Non-Interference Clause to Sustain Anti-Competitive Price Gouging
National LTC Pharmacy Advocacy Group Says Congress Never Intended Clause to be Misused to Undermine Free-Market…Read More.
National LTC Pharmacy Group Urges CMS to Prohibit PBM Pharmacy Fees — Not Reform Them
SCPC Also Says Conceptual “Point of Sale” Policy Solution Not Effective for LTC Pharmacies, LTC Patients as Dually-Eligible Beneficiaries Constitute High Percentage of Patient Population; CMS Authorized to Act under Medicare Part D…Read More.
Senior Care Pharmacy Coalition Comments on Part D Proposed Rule
January 16, 2018 Via Electronic Submission The Honorable Seema Verma, M.P.H. Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attn: CMS-4182-P 7500 Security Boulevard Baltimore, MD 21244 Dear Administrator Verma: The Senior Care Pharmacy Coalition (SCPC) appreciates the opportunity to comment on the proposed rule entitled “Medicare Program: Contract Year read more…
SCPC Outlines PBM Reforms Needed to Protect Consumers, Elderly Patients, LTC Pharmacies
Tells House Energy and Commerce Health Panel Medicare Part D Has Become Oligopolistic Market Benefitting Only PBMs and Their Conglomerates…Read More.
New Report on Prescription Drug Costs: PBMs “Rife with Potential Conflicts of Interest”
SCPC Praises Senate HELP Committee’s Ongoing Examination of Drug Costs, says “PBM Oligopoly Maintains Anti-Competitive Stranglehold on LTC Pharmacies and Patients Under Their Care”…Read More.
New SCPC Comments to FTC Detail Steps to Foster Competition in Pharmaceutical Pricing and Supply Chain
2017 Year-End Focus on Drug Pricing by Senate HELP, House Energy and Commerce Committees Demonstrate Ongoing Saliency of Examining PBM Market Manipulation…Read More.